Weekly Investment Analysts’ Ratings Changes for ArriVent BioPharma (AVBP)

A number of firms have modified their ratings and price targets on shares of ArriVent BioPharma (NASDAQ: AVBP) recently:

• 3/23/2026 – ArriVent BioPharma had its price target raised by B. Riley Financial, Inc. from $37.00 to $45.00. They now have a “buy” rating on the stock.
• 3/12/2026 – ArriVent BioPharma is now covered by BTIG Research. They set a “buy” rating and a $42.00 price target on the stock.
• 3/11/2026 – ArriVent BioPharma was upgraded by BTIG Research to “strong-buy”.
• 3/6/2026 – ArriVent BioPharma had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $50.00 price target on the stock, up from $44.00.
• 3/6/2026 – ArriVent BioPharma had its price target raised by Citigroup Inc. from $31.00 to $33.00. They now have a “buy” rating on the stock.
• 3/6/2026 – ArriVent BioPharma had its price target raised by HC Wainwright from $42.00 to $44.00. They now have a “buy” rating on the stock.

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.